Past Trials
Alzheimer's Disease
A Phase III study for the treatment of mild to moderate Alzheimer's disease in patients who are apolipoprotein E ε4 non-carriers.
Sponsor: Elan Pharmaceuticals, Inc.
A Phase III study for the treatment of mild to moderate Alzheimer's disease in patients who are apolipoprotein E ε4 carriers.
Sponsor: Elan Pharmaceuticals, Inc.
An extension evaluation of the efficacy of Xaliproden in patients with mild to moderate dementia of the Alzheimer's type. Sponsor: Sanofi-Synthelabo
A Phase II trial for treatment of mild to moderate Alzheimer's disease.
Sponsor: Sanofi-aventis
A phase III trial for mild dementia of the Alzheimer's type.
Sponsor: Myriad Pharmaceuticals
A phase II study to evaluate the efficacy and safety of SGS742 in subjects with mild to moderate Alzheimer's disease.
Sponsor: Saegis Pharmaceuticals
Evaluation of the efficacy of Xaliproden in patients with mild to moderate dementia of the Alzheimer's type.
Sponsor: Sanofi-Synthelabo
Evaluation of the safety and efficacy flow-regulated ventriculoperitoneal shunting on progression of Alzheimer's Disease. Device study.
Sponsor: Eunoe
Diabetic Neuropathy
A Phase IIb study for the treatment of diabetic peripheral neuropathy.
Sponsor: Sangamo Biosciences
A Phase II study of Stem-Cell-Mobilization in Subjects with diabetic neuropathy.
Sponsor: Sangamo BioSciences
A Phase II-III study for the treatment of diabetic peripheral neuropathy.
Sponsor: Eisai Pharmaceuticals, Inc.
A Phase II study for the treatment of painful diabetic peripheral neuropathy.
Sponsor: Johnson and Johnson Pharmaceuticals, Inc.
A Phase II study for the treatment of painful diabetic peripheral neuropathy.
Sponsor: Pfizer
A Phase II study for mild diabetic peripheral neuropathy.
Sponsor: Sanofi-aventis
A Phase II study of Stem-Cell-Mobilization in Subjects with Diabetic Neuropathy.
Sponsor: Sangamo BioSciences
A Phase II study for moderate to severe diabetic neuropathy.
Sponsor: Sangamo BioSciences
A Phase II study for mild to moderate diabetic neuropathy.
Sponsor: Sangamo BioSciences
A Phase II study for treatment of mild to moderate diabetic peripheral neuropathy.
Sponsor: Takeda
A Phase II trial for the treatment of mild to moderate diabetic polyneuropathy.
Sponsor: Mitsubishi Pharma America, Inc.
A phase II trial for treatment of painful diabetic neuropathy.
Sponsor: Astellas Pharma
A phase II trial for the treatment of diabetic peripheral neuropathy.
Sponsor: Takeda
A phase II trial for the treatment of painful diabetic peripheral neuropathy.
Sponsor: Schwarz
A phase IV trial of Pregabalin for relief of pain in subjects with painful diabetic peripheral neuropathy.
Sponsor: Pfizer
A phase II study to evaluate the efficacy and safety of SGS742 in subjects with mild to moderate Alzheimer's disease.
Sponsor: Saegis Pharmaceuticals
The evaluation of the efficacy of Xaliproden in patients with mild to moderate dementia of the Alzheimer's type.
Sponsor: Sanofi-Synthelabo
The trial of Fidarestat versus placebo in patients with Diabetic Polyneuropathy.
Sponsor: Sankyo
Parkinson's Disease
An open-label extension study of the safety and clinical utility of IPX066 in subjects with Parkinson's Disease.
Sponsor: IMPAX Pharmaceuticals
A placebo-controlled study to evaluate the safety and efficacy of IPX066 in subjects with Parkinson's Disease.
Sponsor: IMPAX Pharmaceuticals
A study to compare the efficacy and safety of Sumanirole versus placebo in patients with early Parkinson's disease.
Sponsor: Pharmacia
Amyotrophic Later Sclerosis
A Phase I study for the treatment of amyotrophic lateral sclerosis (ALS).
Sponsor: ISIS Pharamceuticals
A Phase II study for the treatment of amyotrophic lateral sclerosis (ALS).
Sponsor: Sangamo BioSciences
A Phase III study for Pseudobulbar Affect (PBA) in patients with Amyotrophic Lateral Sclerosis and Multiple Sclerosis.
Sponsor: Avanir Pharmaceuticals
Evaluation of the safety of AVP-923 (Dextromethorphan/Quinidine) in patients with Pseudobulbar Affect.
Sponsor: Avanir Pharmaceuticals
An Open-Label Safety Study of Recombinant Methionyl Brain Derived Neurotrophic Factor (r-methuBDNF) given by daily subcutaneous injection to patients with Amyotrophic Lateral Sclerosis (ALS).
Sponsor: Amgen Incorporated
Recombinant Methionyl Human Brain Derived Neurotrophic Factor (r-metHuBDNF) given to daily subcutaneous injection to patients with Amyotrophic Lateral Sclerosis (ALS). Phase III.
Sponsor: Amgen Incorporated
Evaluation of Efficacy And Safety of Eliprodil in Patients with Amyotrophic Lateral Sclerosis (ALS). Phase II.
Sponsor: Sanofi
Phase II-III prospective, randomized, double blind placebo-controlled, dose-ranging safety and efficacy study of recombinant human ciliary neurotrophic factor in patients with Amyotrophic Lateral Sclerosis.
Sponsor: Regeneron
Multiple Sclerosis
A Phase III study for Relapsing-Remitting Multiple Sclerosis.
Sponsor: Biogen Idec
A Phase III trial to evaluate the efficacy and safety of 40mg of Copaxone® in the treatment of Relapsing-Remitting Multiple Sclerosis.
Sponsor: Teva Pharmaceuticals
A Phase III study for Pseudobulbar Affect (PBA) in patients with Amyotrophic Lateral Sclerosis and Multiple Sclerosis. Sponsor: Avanir Pharmaceuticals. A study to evaluate the safety, tolerability and efficacy of NBI-5788 in patients with relapsing MS.
Sponsor: Neurocrine Biosciences, Inc.
A study to evaluate the efficacy, tolerability, and safety of 40mg of Copaxone in the treatment of relapsing-remitting MS.
Sponsor: TEVA